International Liver Congress – 2018

aidsmap news from EASL 2018

• Do fatigue and quality of life improve after hepatitis C is cured?

  Hepatitis C symptoms and diagnosis
  Keith Alcorn | 16 May 2018

  Patient-reported outcomes such as fatigue, vitality and mental health improve substantially in the two years following hepatitis C cure for people with cirrhosis, but people with cirrhosis are less likely ...

• Routine clinical use of DAAs highly effective and safe in people with HIV/HCV in Europe

  Hepatitis C treatment
  Michael Carter | 19 April 2018

  “Real life” data from across Europe shows that direct-acting antivirals (DAAs) cure hepatitis C in the vast majority of people with HIV and hepatitis C virus (HCV) co-infection who receive ...

• Curing hepatitis C reduces deaths and liver disease

  Hepatitis C treatment
  Keith Alcorn | 18 April 2018

  Curing hepatitis C infection significantly reduces deaths from liver disease and reduces the incidence of decompensation, two large prospective studies from Italy and Scotland show. The findings were presented on ...

• Direct-acting antivirals bring fewer HCV-related liver transplants, better survival after transplantation, in Europe

  Hepatitis C treatment
  Michael Carter | 16 April 2018

  There has been a steep fall in the number of hepatitis C virus (HCV)-related liver transplants since the introduction of direct-acting antivirals (DAAs), according to European research presented to the ...

• Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy

  Hepatitis C treatment
  Keith Alcorn | 13 April 2018

  An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, ...

• New affordable hepatitis C combination shows 97% cure rate

  Hepatitis C treatment
  Keith Alcorn | 12 April 2018

  The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and could provide a safe and ...